GSK’s Nucala unlikely to get COPD use after panel vote
FDA due to make decision in September
X
GSK’s Nucala unlikely to get COPD use after panel vote
https://pharmaphorum.com/news/gsks-nucala-unlikely-to-get-copd-use-after-panel-vote/
respiratory
AZ suffers setback as NICE slaps restrictions on Fasenra
Fasenra can only be used after GSK rival, NICE says in draft decision
Blow for AZ as late stage COPD trial fails
GSK also hopes to get IL-5 drug approved in COPD
Mixed results from Roche’s key new drugs in Q1
Lacklustre performance from GSK as results season begins
FDA approves expanded use for GSK’s COPD triple therapy
GSK is aiming to revive its respiratory drugs franchise
Sanofi makes double EU filing for cancer and asthma drugs
But NICE rejects Dupixent in eczema